Clinical models for managing bipolar II disorder: Model 2

Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition

Volumn , Issue , 2012, Pages 192-213

  Ketter, Terence A ^a   Wang, Po W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889093211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003315.019     Document Type: Chapter

References (100)

1. Altman, E. G., Hedeker, D., Peterson, J. L. and Davis, J. M. (1997). The Altman Self-Rating Mania Scale. Biological Psychiatry, 42, 948–955.
2. Altshuler, L., Suppes, T., Black, D. et al. (2003). Impact of antidepressant discontinuation at er acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. American Journal of Psychiatry, 160, 1252–1262.
3. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington: American Psychiatric Association.
4. Aronson, R., Of man, H. J., Jef e, R. and Naylor, C. (1996). Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry, 53, 842–848.
5. Baldessarini, R. J., Tondo, L., Floris, G. and Rudas, N. (1997). Reduced morbidity at er gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. American Journal of Psychiatry, 154, 551–553.
6. Baldessarini, R. J., Leahy, l., Arcona, S. et al. (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services, 58, 85–91.
7. Barbini, B., Colombo, C., Benedetti, F. et al. (1998). The unipolar–bipolar dichotomy and the response to sleep deprivation. Psychiatry Research, 79, 43–50.
8. Bauer, M. S., McBride, L., Williford, W. et al. (2006a). Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized efectiveness trial. Psychiatric Services, 57, 927–936.
9. Bauer, M. S., McBride, L., Williford, W. et al. (2006b). Collaborative care for bipolar disorder: part II. Impact on clinical outcome, function, and costs. Psychiatric Services, 57, 937–945.
10. Bauer, M., Kilbourne, A., Greenwald, D. et al. (2009 a). Overcoming Bipolar Disorder: A Comprehensive Workbook for Managing Your Symptoms and Achieving Your Life Goals. Oakland, CA: New Harbinger Pubns.
11. Bauer, M., Pretorius, H. W., Constant, E. et al. (2009b). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, doubleblind study. Journal of Clinical Psychiatry, 70, 540–549.
12. Berman, R. M., Marcus, R. N., Swanink, R. et al. (2007). The Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. Journal of Clinical Psychiatry, 68, 843–853.
13. Bodenheimer, T., Wagner, E. H., Grumbach, K. et al. (2002). Improving primary care for patients with chronic illness. Journal of the American Medical Association, 288, 1775–1779.
14. Bowden, C., Calabrese, J., Ascher, J. et al. (2000). Spectrum of Efficacy of lamotrigine in bipolar disorder: overview of doubleblind placebo-controlled studies. 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10–14.
15. Bowden, C. L., Grunze, H., Mullen, J. et al. (2005). A randomized, double-blind, placebo-controlled Efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry, 66, 111–121.
16. Bowden, C. L., Vieta, E., Ice, K. et al. (2010). Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, doubleblind trial. Journal of Clinical Psychiatry, 71, 130–137.
17. Bressa, G. M. (1994). S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurologica Scandinavica Supplement 1 54, 7–14.
18. Calabrese, J. R., Suppes, T., Bowden, C. et al. (2000). Lamictal 614 study group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Journal of Clinical Psychiatry, 61, 841–850.
19. Calabrese, J. R., Keck, P. E. Jr., MacFadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry, 162, 1351–1360.
20. Chengappa, K. N., Levine, J., Gershon, S. et al. (2000). Inositol as an add-on treatment for bipolar depression. Bipolar Disorder, 2, 47–55.
21. Colom, F., Vieta, E., Madinez-Aran, A. et al. (2003a). A randomized trial on the Efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry, 60, 402–407.
22. Colom, F., Vieta, E., Reinares, M. et al. (2003b). Psychoeducation Efficacy in bipolar disorders: beyond compliance enhancement. Journal of Clinical Psychiatry, 64, 1101–1105.
23. Eden Evins, A., Demopulos, C., Yovel, I. et al. (2006). Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disorder, 8, 168–174.
24. Faedda, G. L., Tondo, L., Baldessarini, J. et al. (1993). Outcome at er rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Archives of General Psychiatry, 50, 448–455.
25. Fieve, R. R. (2006). Bipolar II: Enhance Your Highs, Boost Your Creativity, and Escape the Cycles of Recurrent Depression–The Essential Guide to Recognize and Treat the Mood Swings of h is Increasingly Common Disorder. New York: Rodale Books.
26. Fieve, R. R. (2009). Bipolar Breakthrough:The Essential Guide to Going Beyond Moodswings to Harness Your Highs, Escape the Cycles of Recurrent Depression, and h rive with Bipolar II. New York: Rodale Books.
27. Frangou, S., Lewis, M., McCrone, P. et al. (2006). Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised doubleblind placebo-controlled study. British Journal of Psychiatry, 188, 46–50.
28. Frank, E., Kupfer, D. J., h ase, M. et al. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Archives of General Psychiatry, 62, 996–1004.
29. Frye, M. A., Grunze, H., Suppes, T. et al. (2007). A placebo-controlled evaluation of adjunctive modai nil in the treatment of bipolar depression. American Journal of Psychiatry 164, 1242–1249.
30. Geddes, J. R., Calabrese, J. R. and Goodwin, G. (2009). Lamotrigine for treatment of bipolar depression: independent metaanalysis and meta-regression of individual patient data from i ve randomised trials. British Journal of Psychiatry, 194, 4–9.
31. George, M. S., Lisanby, S. H., Avery, D. et al. (2010). Daily let prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry, 67, 507–516.
32. Ghaemi, S. N., Wingo, A. P., Filkowski, M. et al. (2008). Long-term antidepressant treatment in bipolar disorder: meta-analyses of benei ts and risks. Acta Psychiatrica Scandinavica, 118, 347–356.
33. Gijsman, H. J., Geddes, J. R., Rendell, J. et al. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry, 161, 1537–1547.
34. Gilbody, S., Richards, D., Braeley, S. et al. (2007). Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. Journal of General Internal Medicine, 22, 1596–1602.
35. Goldberg, J. F., Burdick, K. E. and Endick, C. (2004). Preliminary randomized, doubleblind, placebo-controlled trial of pramipexole added to mood stabilizers for treatmentresistant bipolar depression. American Journal of Psychiatry, 161, 564–566.
36. Goodwin, G. M., Bowden, C. L., Calebrese, J. et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry, 65, 432–441.
37. Hirschfeld, R. M., Keck, P. E. Jr., Kramer, M. et al. (2004). Rapid antimanic ef ect of risperidone monotherapy: a 3-week multicenter, double-blind, placebocontrolled trial. American Journal of Psychiatry, 161, 1057–1065.
38. Hirschfeld, R. M., Weisler, R. H., Raines, S. et al. (2006). Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebocontrolled study. Journal of Clinical Psychiatry, 67, 355–362.
39. Keck, P. E., Jr., Marcus, R., Toukodimitris, S. et al. (2003a). A placebo-controlled, double-blind study of the Efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry, 160, 1651–1658.
40. Keck, P. E., Jr., Versiani, M., Potkin, S. e t al. (2003b). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebocontrolled, double-blind, randomized trial. American Journal of Psychiatry, 160, 741–748.
41. Keck, P. E., Calabrese, J. R., McQuade, R. et al. (2006a). A randomized, doubleblind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal of Clinical Psychiatry, 67, 626–637.
42. Keck, P. E., Jr., Mintz, J., McElroy, S. et al. (2006b). Double-blind, randomized, placebo-controlled trials of ethyleicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biological Psychiatry, 60, 1020–1022.
43. Keller, M. B. (2004). Improving the course of illness and promoting continuation of treatment of bipolar disorder. Journal of Clinical Psychiatry, 65 (Suppl 15), 10–14.
44. Kennedy, S. H., Giacobbe, P., Rizvi, S. et al. (2011). Deep brain stimulation for treatment-resistant depression: follow-up at er 3 to 6 years. American Journal of Psychiatry, 168, 502–510.
45. Ketter, T. A. (2010). Handbook of Diagnosis and Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing, Inc.
46. Ketter, T. A., Post, R. M. and Worthington, K. (1991a). Principles of clinically important drug interactions with carbamazepine. Part I. Journal of Clinical Psychopharmacology, 11, 198–203.
47. Ketter, T. A., Post, R. M. and Worthington, K. (1991b). Principles of clinically important drug interactions with carbamazepine. Part II. Journal of Clinical Psychopharmacology, 11, 306–313.
48. Khanna, S., Vieta, E., Lyons, B. et al. (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. British Journal of Psychiatry, 187, 229– 234.
49. Kilbourne, A. M., Post, E. P., Nossek, A. et al. (2008). Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. Psychiatric Services, 59, 760–768.
50. Kripke, D. F. (1998). Light treatment for nonseasonal depression: speed, Efficacy, and combined treatment. Journal of Affective Disorders, 49, 109–117.
51. Lam, D., Wong, G. and Sham, P. (2001). Prodromes, coping strategies and course of illness in bipolar affective disorder– a naturalistic study. Psychological Medicine, 31, 1397–1402.
52. Lam, D. H., Watkins, E. R., Hayward, P. et al. (2003). A randomized controlled study of cognitive therapy for relapse prevention for bipolar afective disorder: outcome of the first year. Archives of General Psychiatry, 60, 145–152.
53. Lam, D. H., Hayward, P., Watkins, E. et al. (2005). Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. American Journal of Psychiatry, 162, 324–329.
54. Linde, K., Berner, M., Egger, M. et al. (2005). St John’ s wort for depression: meta-analysis of randomised controlled trials. British Journal of Psychiatry, 186, 99–107.
55. Marcus, R. N., McQuade, R. D., Carson, W. et al. (2008). heEfficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 156–165.
56. Marcus, R., Khan, A., Rollin, L. et al. (2011). Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disorder, 13, 133–144.
57. Mayberg, H. S., Lozano, A. M., Voon, V. et al. (2005). Deep brain stimulation for treatmentresistant depression. Neuron, 45, 651–660.
58. McIntyre, R. S., Brecher, M., Paulsson, B. et al. (2005). Quetiapine or haloperidol as monotherapy for bipolar mania– a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology, 15, 573–585.
59. Miklowitz, D. J., George, E. L., Richards, J. et al. (2003). A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Archives of General Psychiatry, 60, 904–912.
60. Nemerof, C. B., Evans, D. L., Gyulai, L. et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–912.
61. Nierenberg, A. A., Ostacher, M. J., Calabrese, J. et al. (2006). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized ef ectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry, 163, 210–216.
62. Peet, M. and Harvey, N. S. (1991). Lithium maintenance: 1. A standard education programme for patients. British Journal of Psychiatry, 158, 197–200.
63. Physicians’ Desk Reference (2011). Physicians’ Desk Reference (65th edn). Montvale, NJ: h omson Healthcare, Inc.
64. Potkin, S. G., Keck, P. E. Jr., Segal, S. et al. (2005). Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebocontrolled replication trial. Journal of Clinical Psychopharmacology, 25, 301–310.
65. Quiroz, J. A., Yatham, L. N., Palumbo, J. et al. (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological Psychiatry, 68, 156–162.
66. Rea, M. M., Tompson, M. C., Miklowitz, D. et al. (2003). Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. Journal of Consulting Clinical Psychology, 71, 482–492.
67. Rosenthal, N. E., Sack, D. A., Gillin, J. et al. (1984). Seasonal affective disorder. A description of the syndrome and preliminary indings with light therapy. Archives of General Psychiatry, 41, 72–80.
68. Rush, A. J., Trivedi, M. H., Ibrahim, H. et al. (2003).The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54, 573–583.
69. Rush, A. J., Marangell, L. B., Sackheim, H. et al. (2005). Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biological Psychiatry, 58, 347–354.
70. Sachs, G. S. (1996). Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. Journal of Clinical Psychopharmacology 16 (2 Suppl 1), 32–47.
71. Sachs, G. S. (2003). Decision tree for the treatment of bipolar disorder. Journal of Clinical Psychiatr y, 64 (Suppl 8), 35–40.
72. Sachs, G. S., Grossman, F., Ghaemi, S. et al. (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of Efficacy and safety. American Journal of Psychiatry 159, 1146–1154.
73. Sachs, G., Chengappa, K. N., Suppes, T. et al. (2004). Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disorder, 6, 213–223.
74. Sachs, G., Sanchez, R., Marcus, R. et al. (2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of Psychopharmacology, 20, 536–546.
75. Sachs, G. S., Ice, K. S., Chappell, P. et al. (2011). Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, (in press).
76. Scott, J., Paykel, E., Morris, R. et al. (2006). Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. British Journal of Psychiatry, 188, 313–320.
77. Scott, J., Colom, F. and Vieta, E. et al. (2007). A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. International Journal of Neuropsychopharmacology, 10, 123–129.
78. Sidor, M. M. and Macqueen, G. M. (2010). Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. The Journal of Clinical Psychiatry, 72, 156–167.
79. Simon, G. E., Katon, W. J., Vonkorf, M. et al. (2001). Cost-efectiveness of a collaborative care program for primary care patients with persistent depression. American Journal of Psychiatry, 158, 1638–1644.
80. Simon, G. E., Ludman, E. J., Bauer, M. et al. (2006). Long-term ef ectiveness and cost of a systematic care program for bipolar disorder. Archives of General Psychiatry, 63, 500–508.
81. Stoll, A. L., Severus, W. E., Freeman, M. et al. (1999). Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry, 56, 407–412.
82. Suppes, T., Baldessarini, R. J., Faedda, G. et al. (1991). Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry, 48, 1082–1088.
83. Suppes, T., Hirschfeld, R. M., Vieta, E. et al. (2008). Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebocontrolled studies. World Journal of Biological Psychiatry, 9, 198–211.
84. Suppes, T., Vieta, E., Liu, S. et al. (2009). Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). American Journal of Psychiatry, 166, 476–488.
85. Swann, A. C. (2005). Long-term treatment in bipolar disorder. Journal Clinical Psychiatry, 66 (Suppl 1), 7–12.
86. Swartz, H. A. and Frank, E. (2001). Psychotherapy for bipolar depression: a phase-specii c treatment strategy? Bipolar Disorder, 3, 11–22.
87. Szuba, M. P., Baxter, L. R. Jr., Altshuler, L. et al. (1994). Lithium sustains the acute antidepressant ef ects of sleep deprivation: preliminary indings from a controlled study. Psychiatry Research, 51, 283–295.
88. Taylor, M. J., Carney, S. M., Goodwin, G. et al. (2004). Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 18, 251–256.
89. h ase, M. E., Macfadden, W., Weisler, R. et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebocontrolled study (the BOLDER II study). Journal of Clinical Psychopharmacology, 26, 600–609.
90. Thase, M. E., Corya, S. A., Osuntakun, O. et al. (2007). A randomized, double-blind comparison of olanzapine/l uoxetine combination, olanzapine, and l uoxetine in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry, 68, 224–236.
91. Thase, M. E., Jonas, A., Khan, A. et al. (2008). Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology, 28, 13–20.
92. The UKECT Review Group (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, 361, 799–808.
93. Tohen, M., Vieta, E., Calabrese, J. et al. (2003). Efficacy of olanzapine and olanzapine– l uoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry, 60, 1079–1088.
94. Vieta, E., Suppes, T., Eggens, I. et al. (2008a). Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Journal of Affective Disorders, 109, 251–263.
95. Vieta, E., T’Joen, C., McQuade, R. et al. (2008b). Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: A placebocontrolled study. American Journal of Psychiatry, 165, 1316–1325.
96. Wisniewski, S. R., Rush, A. J., Balasubramani, G. et al. (2006b). Self-rated global measure of the frequency, intensity, and burden of side ef ects. Journal of Psychiatric Practice, 12, 71–79.
97. Wu, J. C. and Bunney W. E. (1990).The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. American Journal of Psychiatry, 147, 14–21.
98. Yatham, L. N., G rossman, F., Augustyns, I. e t al. (2003). Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. British Journal of Psychiatry, 182, 141–147.
99. Yatham, L. N., Paulsson, B., Mullen, J. et al. (2004). Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. Journal of Clinical Psychopharmacology, 24, 599–606.
100. Zarate, C. A., Jr., Payne, J. L., Singh, J. et al. (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.